Valley National Advisers’s Takeda Pharmaceutical TAK Stock Holding History

Valley National Advisers’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$1K	–	1121
2023 Q2	$1K	Hold	5	–	–	﹤0.01%	937
2023 Q1	$0	Hold	5	–	–	﹤0.01%	973
2022 Q4	$0	Sell	5 -1,399	-100%	-$19.5K	﹤0.01%	973
2022 Q3	$18K	Hold	1,404	–	–	﹤0.01%	513
2022 Q2	$20K	Buy	1,404 +1,399	+27,980%	+$20K	﹤0.01%	486
2022 Q1	$0	Hold	5	–	–	﹤0.01%	982
2021 Q4	$0	Hold	5	–	–	﹤0.01%	962
2021 Q3	$0	Sell	5 -55	-92%	-$923	﹤0.01%	936
2021 Q2	$1K	Hold	60	–	–	﹤0.01%	851
2021 Q1	$1K	Hold	60	–	–	﹤0.01%	816
2020 Q4	$1K	Hold	60	–	–	﹤0.01%	773
2020 Q3	$1K	Hold	60	–	–	﹤0.01%	742
2020 Q2	$1K	Hold	60	–	–	﹤0.01%	745
2020 Q1	$1K	Hold	60	–	–	﹤0.01%	727
2019 Q4	$1K	Hold	60	–	–	﹤0.01%	730
2019 Q3	$1K	Hold	60	–	–	﹤0.01%	735
2019 Q2	$1K	Hold	60	–	–	﹤0.01%	705
2019 Q1	$1K	Buy	+60	New	+$1.21K	﹤0.01%	704

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valley National Advisers's TAK Position: Q3 2023 in Review

Valley National Advisers sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 5 shares — an estimated $1K sold.

Valley National Advisers first reported a position in TAK in Q1 2019 and held it in 18 quarters. The position peaked at $20K in Q2 2022. 312 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Valley National Advisers reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Valley National Advisers sold 5 Takeda Pharmaceutical shares in Q3 2023, an estimated $1K.
Valley National Advisers first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 18 quarters.
Valley National Advisers's Takeda Pharmaceutical position peaked at $20K in Q2 2022.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Valley National Advisers's 13F filing for Q3 2023, filed 13 Nov 2023.